false Q2 0001478320 --12-31 Non-accelerated Filer false 270907024 270907024 92656029 561333000 12208731 1000 24972000 166000 249423000 224616000 140000 140000 338113 823000 823000 134065 100000 3000 3000 3000 3000 3000 5547000 5547000 74000 74000 24884000 24884000 92790094 560858000 12841536 37902000 107000 295908000 258112000 883845 1880000 1880000 249643 109000 964000 964000 964000 6378000 6378000 489000 489000 34045000 34045000 P1Y9M21D P2Y3M21D us-gaap:ValuationTechniqueOptionPricingModelMember us-gaap:ValuationTechniqueOptionPricingModelMember P6Y21D P6Y1M28D 0001478320 2019-01-01 2019-06-30 xbrli:shares 0001478320 2019-07-31 iso4217:USD 0001478320 2019-06-30 0001478320 2018-12-31 iso4217:USD xbrli:shares 0001478320 adpt:SequencingRevenueMember 2019-04-01 2019-06-30 0001478320 adpt:SequencingRevenueMember 2018-04-01 2018-06-30 0001478320 adpt:SequencingRevenueMember 2019-01-01 2019-06-30 0001478320 adpt:SequencingRevenueMember 2018-01-01 2018-06-30 0001478320 adpt:DevelopmentRevenueMember 2019-04-01 2019-06-30 0001478320 adpt:DevelopmentRevenueMember 2018-04-01 2018-06-30 0001478320 adpt:DevelopmentRevenueMember 2019-01-01 2019-06-30 0001478320 adpt:DevelopmentRevenueMember 2018-01-01 2018-06-30 0001478320 2019-04-01 2019-06-30 0001478320 2018-04-01 2018-06-30 0001478320 2018-01-01 2018-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2018-03-31 0001478320 us-gaap:CommonStockMember 2018-03-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001478320 us-gaap:RetainedEarningsMember 2018-03-31 0001478320 2018-03-31 0001478320 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001478320 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2018-06-30 0001478320 us-gaap:CommonStockMember 2018-06-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001478320 us-gaap:RetainedEarningsMember 2018-06-30 0001478320 2018-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-03-31 0001478320 us-gaap:CommonStockMember 2019-03-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001478320 us-gaap:RetainedEarningsMember 2019-03-31 0001478320 2019-03-31 0001478320 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-04-01 2019-06-30 0001478320 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-06-30 0001478320 us-gaap:CommonStockMember 2019-06-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001478320 us-gaap:RetainedEarningsMember 2019-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2017-12-31 0001478320 us-gaap:CommonStockMember 2017-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001478320 us-gaap:RetainedEarningsMember 2017-12-31 0001478320 2017-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001478320 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001478320 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001478320 us-gaap:CommonStockMember 2018-12-31 0001478320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001478320 us-gaap:RetainedEarningsMember 2018-12-31 0001478320 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001478320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001478320 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-06-30 0001478320 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001478320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember 2019-01-01 2019-06-30 0001478320 adpt:SeriesEOneConvertiblePreferredStockMember adpt:SequentaSEquityIncentivePlanMember 2019-01-01 2019-06-30 0001478320 us-gaap:SubsequentEventMember us-gaap:IPOMember 2019-07-01 2019-07-01 0001478320 us-gaap:SubsequentEventMember us-gaap:IPOMember 2019-07-01 0001478320 us-gaap:SubsequentEventMember adpt:TwoThousandAndNineteenEquityIncentivePlanMember 2019-07-01 xbrli:pure 0001478320 adpt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-04-01 2019-06-30 0001478320 adpt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-04-01 2018-06-30 0001478320 adpt:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-06-30 0001478320 adpt:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-06-30 0001478320 adpt:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-04-01 2018-06-30 0001478320 adpt:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001478320 adpt:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001478320 adpt:GenentechIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-04-01 2019-06-30 0001478320 adpt:GenentechIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-06-30 adpt:Performance_Obligation 0001478320 adpt:SequencingRevenueFromCoveragePolicyMember 2019-04-01 2019-06-30 0001478320 adpt:SequencingRevenueFromCoveragePolicyMember 2019-01-01 2019-06-30 0001478320 adpt:SequencingRevenueFromTestDeliverMember 2019-04-01 2019-06-30 0001478320 adpt:SequencingRevenueFromTestDeliverMember 2019-01-01 2019-06-30 0001478320 adpt:RestrictedCashAndOtherAssetsMember 2019-06-30 0001478320 us-gaap:AccountingStandardsUpdate201609Member 2019-01-01 2019-06-30 0001478320 adpt:TranslationalDevelopmentAgreementsMember srt:MaximumMember 2015-12-18 0001478320 adpt:TranslationalDevelopmentAgreementsMember 2015-12-18 2015-12-18 0001478320 adpt:TranslationalDevelopmentAgreementsMember 2015-12-18 0001478320 adpt:TranslationalDevelopmentAgreementsMember 2019-04-01 2019-06-30 0001478320 adpt:TranslationalDevelopmentAgreementsMember 2018-04-01 2018-06-30 0001478320 adpt:TranslationalDevelopmentAgreementsMember 2019-01-01 2019-06-30 0001478320 adpt:TranslationalDevelopmentAgreementsMember 2018-01-01 2018-06-30 0001478320 adpt:MRDDevelopmentAgreementsMember 2019-04-01 2019-06-30 0001478320 adpt:MRDDevelopmentAgreementsMember 2018-04-01 2018-06-30 0001478320 adpt:MRDDevelopmentAgreementsMember 2019-01-01 2019-06-30 0001478320 adpt:MRDDevelopmentAgreementsMember 2018-01-01 2018-06-30 0001478320 adpt:MRDDevelopmentAgreementsMember srt:MaximumMember 2019-06-30 0001478320 adpt:GenentechCollaborationAgreementMember 2019-02-01 2019-02-28 0001478320 adpt:GenentechCollaborationAgreementMember srt:MinimumMember 2019-06-30 0001478320 adpt:GenentechCollaborationAgreementMember adpt:RegulatoryMilestonesMember srt:MaximumMember 2019-06-30 0001478320 adpt:GenentechCollaborationAgreementMember adpt:DevelopmentMilestonesMember srt:MaximumMember 2019-06-30 0001478320 adpt:GenentechCollaborationAgreementMember adpt:CommercialMilestonesMember srt:MaximumMember 2019-06-30 0001478320 adpt:GenentechCollaborationAgreementMember 2019-01-01 2019-06-30 0001478320 adpt:GenentechCollaborationAgreementMember srt:MinimumMember 2019-01-01 2019-06-30 0001478320 adpt:GenentechCollaborationAgreementMember srt:MaximumMember 2019-01-01 2019-06-30 0001478320 adpt:GenentechCollaborationAgreementMember 2019-04-01 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member adpt:ConvertiblePreferredStockWarrantLiabilityMember 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member adpt:ConvertiblePreferredStockWarrantLiabilityMember 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2018-12-31 0001478320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0001478320 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2019-06-30 0001478320 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0001478320 adpt:ConvertiblePreferredStockWarrantLiabilityMember 2019-01-01 2019-06-30 0001478320 us-gaap:MeasurementInputExercisePriceMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2019-06-30 0001478320 us-gaap:MeasurementInputExercisePriceMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2018-12-31 0001478320 us-gaap:MeasurementInputExpectedTermMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2019-06-30 0001478320 us-gaap:MeasurementInputExpectedTermMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2018-12-31 0001478320 us-gaap:MeasurementInputRiskFreeInterestRateMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2019-06-30 0001478320 us-gaap:MeasurementInputRiskFreeInterestRateMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2018-12-31 0001478320 us-gaap:MeasurementInputPriceVolatilityMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2019-06-30 0001478320 us-gaap:MeasurementInputPriceVolatilityMember adpt:ConvertiblePreferredStockWarrantLiabilityMember 2018-12-31 0001478320 us-gaap:CommercialPaperMember 2019-06-30 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0001478320 us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001478320 us-gaap:CommercialPaperMember 2018-12-31 0001478320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001478320 us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001478320 2015-12-31 0001478320 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0001478320 us-gaap:IntellectualPropertyMember 2019-06-30 0001478320 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001478320 us-gaap:IntellectualPropertyMember 2018-12-31 0001478320 us-gaap:IntellectualPropertyMember 2019-01-01 2019-06-30 0001478320 adpt:SequencingRevenueMember 2019-06-30 0001478320 adpt:SequencingRevenueMember 2018-12-31 0001478320 adpt:DevelopmentRevenueMember 2019-06-30 0001478320 adpt:DevelopmentRevenueMember 2018-12-31 0001478320 adpt:DevelopmentRevenueMember adpt:GenentechIncMember 2019-06-30 0001478320 adpt:GenentechIncMember srt:MinimumMember 2019-07-01 2019-06-30 0001478320 adpt:GenentechIncMember srt:MaximumMember 2019-07-01 2019-06-30 0001478320 2019-06-29 2019-06-30 0001478320 adpt:SeriesAConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:SeriesBConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:SeriesCConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:SeriesDConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:SeriesEConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:SeriesEOneConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:SeriesFConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:SeriesFOneConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:SeriesEOneConvertiblePreferredStockMember 2019-01-01 2019-06-30 adpt:Vote 0001478320 adpt:CommonStockOptionsMember 2019-06-30 0001478320 us-gaap:EmployeeStockOptionMember 2019-06-30 0001478320 us-gaap:WarrantMember 2019-06-30 0001478320 srt:MaximumMember us-gaap:CommonStockMember 2019-06-30 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2019-01-01 2019-06-30 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember 2019-06-30 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember 2018-12-31 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember 2019-06-30 0001478320 adpt:SequentaSEquityIncentivePlanMember adpt:SeriesEOneConvertiblePreferredStockMember 2018-12-31 0001478320 adpt:SequentaSEquityIncentivePlanMember adpt:SeriesEOneConvertiblePreferredStockMember 2019-06-30 0001478320 adpt:TwoThousandAndNineEquityIncentivePlanMember 2018-01-01 2018-06-30 0001478320 us-gaap:ValuationTechniqueOptionPricingModelMember 2019-01-01 2019-06-30 0001478320 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001478320 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001478320 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001478320 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001478320 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001478320 us-gaap:SellingAndMarketingExpenseMember 2019-04-01 2019-06-30 0001478320 us-gaap:SellingAndMarketingExpenseMember 2018-04-01 2018-06-30 0001478320 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-06-30 0001478320 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-06-30 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001478320 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001478320 adpt:SeriesEOneConvertiblePreferredStockMember 2019-04-01 2019-06-30 0001478320 adpt:SeriesEOneConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001478320 adpt:SeriesEOneConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001478320 adpt:TwoThousandAndNinePlanMember us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001478320 adpt:TwoThousandAndNinePlanMember us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001478320 adpt:TwoThousandAndNinePlanMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001478320 adpt:TwoThousandAndNinePlanMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001478320 adpt:TwoThousandAndEightPlanMember us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001478320 adpt:TwoThousandAndEightPlanMember us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001478320 adpt:TwoThousandAndEightPlanMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001478320 adpt:TwoThousandAndEightPlanMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001478320 adpt:CommonStockWarrantsMember 2019-04-01 2019-06-30 0001478320 adpt:CommonStockWarrantsMember 2018-04-01 2018-06-30 0001478320 adpt:CommonStockWarrantsMember 2019-01-01 2019-06-30 0001478320 adpt:CommonStockWarrantsMember 2018-01-01 2018-06-30 0001478320 adpt:ConvertiblePreferredStockWarrantsMember 2019-04-01 2019-06-30 0001478320 adpt:ConvertiblePreferredStockWarrantsMember 2018-04-01 2018-06-30 0001478320 adpt:ConvertiblePreferredStockWarrantsMember 2019-01-01 2019-06-30 0001478320 adpt:ConvertiblePreferredStockWarrantsMember 2018-01-01 2018-06-30 utr:sqft 0001478320 us-gaap:SubsequentEventMember 2019-08-13

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____to _____

Commission File Number: 001-38957

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

 

Washington

27-0907024

( State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

1551 Eastlake Avenue East, Suite 200

Seattle, Washington

98102

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (206) 659-0067

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of July 31, 2019, the registrant had 124,287,992 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 


Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

4

Item 1.

Financial Statements (Unaudited)

4

 

Condensed Balance Sheets

4

 

Condensed Statements of Operations

5

 

Condensed Statements of Comprehensive Loss

6

 

Condensed Statements of Convertible Preferred Stock and Shareholders’ Deficit

7

 

Condensed Statements of Cash Flows

9

 

Notes to Unaudited Condensed Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

25

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

36

Item 4.

Controls and Procedures

36

PART II.

OTHER INFORMATION

37

Item 1.

Legal Proceedings

37

Item 1A.

Risk Factors

37

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

37

Item 3.

Defaults Upon Senior Securities

37

Item 4.

Mine Safety Disclosures

38

Item 5.

Other Information

38

Item 6.

Exhibits

38

Signatures

39

 


Adaptive Biotechnologies Corporation

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this report other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.  In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this report and in other documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.  As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this report represent our views as of the date of this report. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Unless otherwise stated or the context otherwise indicates, references to “we,” “us,” “our” and similar references refer to Adaptive Biotechnologies Corporation.

 

 

3


Adaptive Biotechnologies Corporation

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Condensed Balance Sheets

(in thousands, except share and per share amounts)

 

 

 

June 30,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

48,458

 

 

$

55,030

 

Short-term marketable securities

 

 

374,543

 

 

 

109,988

 

Accounts receivable, net

 

 

7,252

 

 

 

4,807

 

Inventory

 

 

8,004

 

 

 

7,838

 

Prepaid expenses and other current assets

 

 

4,044

 

 

 

3,055

 

Total current assets

 

 

442,301

 

 

 

180,718

 

Long-term assets

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

22,298

 

 

 

19,125

 

Restricted cash and other assets

 

 

5,040

 

 

 

247

 

Intangible assets, net

 

 

12,784

 

 

 

13,626

 

Goodwill

 

 

118,972

 

 

 

118,972

 

Total assets

 

$

601,395

 

 

$

332,688

 

Liabilities, convertible preferred stock and shareholders’ deficit

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,944

 

 

$

1,793

 

Accrued liabilities

 

 

5,019

 

 

 

2,562

 

Accrued compensation and benefits

 

 

4,429

 

 

 

4,641

 

Current portion of deferred rent

 

 

1,276

 

 

 

1,109

 

Current deferred revenue

 

 

61,194

 

 

 

12,695

 

Total current liabilities

 

 

74,862

 

 

 

22,800

 

Long-term liabilities

 

 

 

 

 

 

 

 

Convertible preferred stock warrant liability

 

 

2,602

 

 

 

336

 

Deferred rent liability, less current portion

 

 

5,455

 

 

 

6,102

 

Deferred revenue, less current portion

 

 

240,919

 

 

 

704

 

Total liabilities

 

 

323,838

 

 

 

29,942

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

 

 

Convertible preferred stock: $0.0001 par value, 93,762,517 shares authorized

   at June 30, 2019 and December 31, 2018, respectively; 93,039,737 and

   92,790,094 shares issued and outstanding at June 30, 2019 and December

   31, 2018, respectively; aggregate liquidation preference of $574,374 and

   $572,866 at June 30, 2019 and December 31, 2018, respectively

 

 

561,931

 

 

 

560,858

 

Shareholders’ deficit

 

 

 

 

 

 

 

 

Common stock: $0.0001 par value, 131,000,000 shares authorized at

   June 30, 2019 and December 31, 2018, respectively; 13,725,381 and

   12,841,536 shares issued and outstanding at June 30, 2019 and December

   31, 2018, respectively

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

46,160

 

 

 

37,902

 

Accumulated other comprehensive gain (loss)

 

 

382

 

 

 

(107

)

Accumulated deficit

 

 

(330,917

)

 

 

(295,908

)

Total shareholders’ deficit

 

 

(284,374

)

 

 

(258,112

)

Total liabilities, convertible preferred stock and shareholders’

   deficit

 

$

601,395

 

 

$

332,688

 

 

The accompanying notes are an integral part of these financial statements.

 

 

4


Adaptive Biotechnologies Corporation

 

Condensed Statements of Operations

(in thousands, except share and per share amounts)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

 

 

(unaudited)

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sequencing revenue

 

$

11,865

 

 

$

8,281

 

 

$

17,948

 

 

$

14,061

 

Development revenue

 

 

10,273

 

 

 

3,287

 

 

 

16,856

 

 

 

7,222

 

Total revenue

 

 

22,138

 

 

 

11,568

 

 

 

34,804

 

 

 

21,283

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

5,734

 

 

 

5,044

 

 

 

10,722

 

 

 

9,033

 

Research and development

 

 

16,527

 

 

 

9,452

 

 

 

29,010

 

 

 

18,307

 

Sales and marketing

 

 

8,897

 

 

 

5,329

 

 

 

16,714

 

 

 

10,376

 

General and administrative

 

 

6,662

 

 

 

4,632

 

 

 

13,666

 

 

 

9,175

 

Amortization of intangible assets

 

 

423

 

 

 

424

 

 

 

842

 

 

 

843

 

Total operating expenses

 

 

38,243

 

 

 

24,881

 

 

 

70,954

 

 

 

47,734

 

Loss from operations

 

 

(16,105

)

 

 

(13,313

)

 

 

(36,150

)

 

 

(26,451

)

Interest and other income, net

 

 

446

 

 

 

820

 

 

 

2,105

 

 

 

1,567

 

Net loss

 

 

(15,659

)

 

 

(12,493

)

 

 

(34,045

)

 

 

(24,884

)

Fair value adjustment to Series E-1 convertible preferred stock options

 

 

(710

)

 

 

(2

)

 

 

(964

)

 

 

2

 

Net loss attributable to common shareholders

 

$

(16,369

)

 

$

(12,495

)

 

$

(35,009

)

 

$

(24,882

)

Net loss per share attributable to common shareholders, basic and

   diluted

 

$

(1.23

)

 

$

(1.01

)

 

$

(2.68

)

 

$

(2.02

)

Weighted-average shares used in computing net loss per share

   attributable to common shareholders, basic and diluted

 

 

13,279,324

 

 

 

12,385,888

 

 

 

13,074,692

 

 

 

12,334,227

 

 

The accompanying notes are an integral part of these financial statements.

 

5


Adaptive Biotechnologies Corporation

 

 

Condensed Statements of Comprehensive Loss

(in thousands)

 

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

 

 

(unaudited)

 

Net loss

 

$

(15,659

)

 

$

(12,493

)

 

$

(34,045

)

 

$

(24,884

)

Change in unrealized gain (loss) on investments

 

 

290

 

 

 

43

 

 

 

489

 

 

 

(74

)

Comprehensive loss

 

$

(15,369

)

 

$

(12,450

)

 

$

(33,556

)

 

$

(24,958

)

 

The accompanying notes are an integral part of these financial statements.

 

6


Adaptive Biotechnologies Corporation

 

Condensed Statements of Convertible Preferred Stock and Shareholders’ Deficit

(in thousands, except share amounts)

 

 

 

 

Convertible

preferred stock

 

 

 

Common stock

 

 

Additional

paid-in

 

 

Accumulated

other

comprehensive

 

 

Accumulated

 

 

Total

shareholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

(loss) income

 

 

deficit

 

 

deficit

 

Balance as of March 31, 2018 (unaudited)

 

 

92,745,734

 

 

$

561,396

 

 

 

 

12,301,844

 

 

$

1

 

 

$

28,620

 

 

$

(283

)

 

$

(261,950

)

 

$

(233,612

)

Issuance of common stock for cash upon exercise of stock options (unaudited)

 

 

 

 

 

 

 

 

 

245,000

 

 

 

 

 

 

415

 

 

 

 

 

 

 

 

 

415

 

Issuance of Series E-1 convertible preferred stock for cash upon

   exercise of Series E-1 convertible preferred stock options at fair value (unaudited)

 

 

44,360

 

 

 

35

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested Series E-1 convertible preferred stock option forfeitures (unaudited)

 

 

 

 

 

(767

)

 

 

 

 

 

 

 

 

 

476

 

 

 

 

 

 

291

 

 

 

767

 

Series E-1 convertible preferred stock option share-based compensation (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

1

 

Adjustment to redemption value for vested Series E-1 convertible

   preferred stock options (unaudited)

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

 

 

 

(1

)

Change in redemption value for vested Series E-1 convertible

   preferred stock options (unaudited)

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2

)

 

 

(2

)

Common stock option share-based compensation (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,447

 

 

 

 

 

 

 

 

 

2,447

 

Other comprehensive income (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

43

 

 

 

 

 

 

43

 

Net loss (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(12,493

)

 

 

(12,493

)

Balance as of June 30, 2018 (unaudited)

 

 

92,790,094

 

 

$

560,667

 

 

 

 

12,546,844

 

 

$

1

 

 

$

31,958

 

 

$

(240

)

 

$

(274,154

)

 

$

(242,435

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance as of March 31, 2019 (unaudited)

 

 

93,023,694

 

 

$

561,210

 

 

 

 

12,930,536

 

 

$

1

 

 

$

40,981

 

 

$

92

 

 

$

(314,548

)

 

$

(273,474

)

Issuance of common stock for cash upon exercise of stock options (unaudited)

 

 

 

 

 

 

 

 

 

794,845

 

 

 

 

 

 

1,847

 

 

 

 

 

 

 

 

 

1,847

 

Issuance of Series E-1 convertible preferred stock for cash upon

   exercise of Series E-1 convertible preferred stock options at fair value (unaudited)

 

 

16,043

 

 

 

11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in redemption value for vested Series E-1 convertible

   preferred stock options (unaudited)

 

 

 

 

 

710

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(710

)

 

 

(710

)

Common stock option share-based compensation (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,332

 

 

 

 

 

 

 

 

 

3,332

 

Other comprehensive income (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

290

 

 

 

 

 

 

290

 

Net loss (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(15,659

)

 

 

(15,659

)

Balance as of June 30, 2019 (unaudited)

 

 

93,039,737

 

 

$

561,931

 

 

 

 

13,725,381

 

 

$

1

 

 

$

46,160

 

 

$

382

 

 

$

(330,917

)

 

$

(284,374

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7


Adaptive Biotechnologies Corporation

 

Condensed Statements of Convertible Preferred Stock and Shareholders’ Deficit (Continued)

(in thousands, except share amounts)

 

Balance as of December 31, 2017

 

 

92,656,029

 

 

$

561,333

 

 

 

 

12,208,731

 

 

$

1

 

 

$

24,972

 

 

$

(166

)

 

$

(249,423

)

 

$

(224,616

)

Adjustments to accumulated deficit for adoption of guidance on accounting for share-based payment transactions (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

140

 

 

 

 

 

 

(140

)

 

 

 

Issuance of common stock for cash upon exercise of stock options (unaudited)

 

 

 

 

 

 

 

 

 

338,113

 

 

 

 

 

 

823

 

 

 

 

 

 

 

 

 

823

 

Issuance of Series E-1 convertible preferred stock for cash upon

   exercise of Series E-1 convertible preferred stock options at fair value (unaudited)

 

 

134,065

 

 

 

100

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested Series E-1 convertible preferred stock option forfeitures (unaudited)

 

 

 

 

 

(767

)

 

 

 

 

 

 

 

 

 

476

 

 

 

 

 

 

291

 

 

 

767

 

Series E-1 convertible preferred stock option share-based compensation (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

3

 

Adjustment to redemption value for vested Series E-1 convertible

   preferred stock options (unaudited)

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

 

(3

)

 

 

 

 

 

 

 

 

(3

)

Change in redemption value for vested Series E-1 convertible

   preferred stock options (unaudited)

 

 

 

 

 

(2

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

2

 

Common stock option share-based compensation (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,547

 

 

 

 

 

 

 

 

 

5,547

 

Other comprehensive loss (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(74

)